Overview
MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a 16-amino-acid peptide that is unusual in being encoded by mitochondrial DNA rather than the nuclear genome. It belongs to a class known as mitochondrial-derived peptides.
Since its identification, MOTS-c has been studied extensively in preclinical research as a signaling molecule linking mitochondrial status to whole-cell and whole-organism metabolism. It is frequently cited in aging and metabolic-research literature.
Mechanism of action
MOTS-c has been studied as a regulator of metabolic homeostasis, with reported links to the AMP-activated protein kinase (AMPK) pathway, a central cellular energy sensor. Research models describe MOTS-c influencing folate and methionine metabolism and, through downstream signaling, glucose handling and insulin sensitivity.
MOTS-c has also been reported to translocate to the cell nucleus under metabolic stress, where studies describe it interacting with stress-response transcriptional programs. The complete network of its actions remains an active research area.
Research findings
- Identified as a mitochondrial-encoded peptide with metabolic-regulatory activity.
- Studied for connections to the AMPK energy-sensing pathway.
- Examined in models for effects on insulin sensitivity and glucose metabolism.
- Reported to translocate to the nucleus and engage stress-response gene programs.
- Investigated in aging and exercise-physiology research contexts.
Research context
Reports describe MOTS-c as having a relatively short circulating presence, with pharmacokinetic parameters that are not fully characterized and that vary across study models. Study dose ranges in preclinical work differ by species, route, and endpoint, and no standardized framework spans the literature. Most published data are preclinical. This is a research reference only. Not approved for human use outside regulated settings; consult the primary literature.
Handling & storage
Lyophilized peptide material is generally reported as stable when stored sealed, dry, cold, and protected from light, with frozen storage recommended for long-term laboratory storage. Reconstituted peptide solutions are typically described as less stable and stored refrigerated for shorter periods. Standard peptide-handling practice, including limiting freeze-thaw cycles, applies.
Reported safety signals
Because most published evidence is preclinical, the human side-effect profile of MOTS-c is not established and is best described as not well characterized. As with any investigational peptide, effects outside controlled research settings are unknown.
Studied alongside
In research and reference contexts, MOTS-c is often discussed alongside other metabolically studied compounds, including the NNMT inhibitor 5-amino-1MQ and growth-hormone fragment peptides. It is mechanistically distinct from GLP-1 and amylin pathway agents such as semaglutide and cagrilintide, which are sometimes referenced for comparison.
At a glance
Research strengths
- Naturally occurring, well-characterized mitochondrial-derived peptide.
- Defined links to the AMPK energy-sensing pathway in research.
- Broad preclinical literature across metabolism and aging.
- Known sequence and molecular identity.
Limitations & cautions
- Pharmacokinetics, including half-life, are not fully characterized.
- Most evidence is preclinical, with limited human data.
- Not approved for therapeutic use; research-only status.
- Long-term safety profile is unknown.
